Littelfuse to Host 2026 Investor Day Today

CHICAGO--(BUSINESS WIRE)-- Littelfuse, Inc. (NASDAQ: LFUS), a leader in developing smart solutions that enable safe and efficient electrical energy transfer, will host an Investor Day in New York City today, Thursday, May 14, 2026. Presentations are expected to begin at 9:00 a.m. ET and conclude at 12:00 p.m. ET.

Greg Henderson, President and CEO, Abhi Khandelwal, Executive Vice President and CFO, and other members of the executive leadership team will present an in-depth review of the company’s business strategy, growth drivers, and objectives for our 2030 Ambition. The event will also feature interactive Q&A session.

The event will be livestreamed, and a replay of the event will be available within 24 hours following the event’s conclusion through this website: https://app.webinar.net/P5x78rqRM2q. Presentation materials will also be available today on the Littelfuse’s Investor Relations website at https://investor.littelfuse.com/events-and-presentations.

About Littelfuse
Littelfuse, Inc. (NASDAQ: LFUS) is a diversified, industrial technology manufacturing company empowering a sustainable, connected, and safer world. Across more than 20 countries, and with approximately 17,000 global associates, we partner with customers to design and deliver innovative, reliable solutions. Serving over 100,000 end customers, our products are found in a variety of industrial, transportation and electronics end markets – everywhere, every day. Learn more at Littelfuse.com.

LFUS-F

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514714986/en/

David Kelley
224-727-2535
[email protected]

Source: Littelfuse, Inc.

You May Also Be Interested In

• AscentHR Acquires OS HRS to Strengthen APAC Payroll Leadership
• DPC Dash - Domino's Pizza China Deepens Market Leadership with Continued Store Expansion and Improving Sales Momentum in Q2 2026
• Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formu